Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Rare cancers and tumour agnostic oncology

EMA vis-à-vis agnostic oncology


20 Mar 2023


Rare cancers and tumour agnostic oncology


Cancer Research

Tumour Site


Francesco Pignatti


F. Pignatti

Author affiliations

  • Office Of Oncology And Haematology, European Medicines Agency - Amsterdam, 1083 HN - Amsterdam/NL


This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.